Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 186.43 and traded as low as GBX 180. Faron Pharmaceuticals Oy shares last traded at GBX 187.50, with a volume of 3,425 shares.
Faron Pharmaceuticals Oy Stock Performance
The stock has a market cap of £213.57 million, a P/E ratio of -6.94 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55. The stock has a 50 day simple moving average of GBX 186.43 and a 200 day simple moving average of GBX 202.66.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
- Five stocks we like better than Faron Pharmaceuticals Oy
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Is American Express the Credit Stock For a K-Shaped Economy?
- The 3 Best Retail Stocks to Shop for in August
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
